PLK1 expression was an independent prognostic factor. Patients with PLK1-positive and high PCNA-LI tumors showed a signifi cantly poorer prognosis than patients with PLK1-negative and/or low PCNA-LI tumors. Furthermore, the prognosis of patients with PLK1-and p53-positive tumors was signifi cantly worse than that of patients with PLK1-and p53-negative or PLK1-negative and p53-positive tumors. Conclusion: PLK1 expression may be a critical indicator of a poor prognosis in patients with gastric carcinoma.
PLK1 Expression in Gastric Carcinoma
Polo-like kinases (PLKs) belong to a family of serine/ threonine kinases and are the human counterparts of polo in Drosophila melanogaster and CDC5 in Saccharomyces cerevisiae [2, 3] . Of the four known human PLKs, PLK1 is the best-characterized PLK to date. PLK1 has been shown to be intimately involved in spindle formation and chromosome segregation during mitosis and, therefore, in the regulation of the cell cycle [4, 5] . The activity of PLK1 has been found to be elevated in tissues and cells with a high mitotic index, including carcinoma cells, and PLK1 expression levels are believed to have a prognostic value for outcome in patients with some carcinomas [6, 7] . However, the roles of PLK1 in the development or progression of gastric carcinoma are not well understood. In the current study, we determined PLK1 expression to elucidate its clinical signifi cance in gastric carcinoma.
Materials and Methods

Medium and Cell Lines
A complete culture medium (CM) consisting of RPMI 1640 (Cosmo Bio, Tokyo, Japan), 1% penicillin/streptomycin (Invitrogen, Carlsbad, Calif., USA) and 10% heat-inactivated fetal bovine serum (Thermo Trace, Melbourne, Australia) was used. Six human gastric cancer cell lines (MKN-1, MKN-28, MKN-45, MKN-74, TMK1 and KATO-III) were purchased from the RIKEN Cell Bank (Tsukuba, Japan) and maintained in CM.
Western Blot Analysis
Cells were lysed in sample buffer (Tris-HCl, pH 6.8, sodium dodecyl sulfate, glycerol and bromophenol blue) containing protease inhibitors (Complete Mini; Roche Molecular Biochemicals, Mannheim, Germany). Following sonication of the samples, the total protein concentrations were quantifi ed using a bicinchoninic acid (BCA) Protein Assay Kit (Pierce Biotechnology, Rockford, Ill., USA). After boiling the samples, aliquots (60 g protein/lane) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently blotted onto a polyvinylidene difl uoride membrane. The membrane was blocked with 5% non-fat dry milk in Tris-buffered saline (TBS) containing 0.05% Tween 20 for 1 h, and then incubated with a rabbit polyclonal anti-human PLK1 antibody (1: 1,000 dilution; Oncogene, San Diego, Calif., USA) overnight at 4 ° C. After three washes with TBS containing 0.05% Tween 20 and 5% non-fat dry milk for 10 min each, the membrane was incubated with a secondary antibody (1: 2,000 dilution in TBS) for 1 h. After another three washes with TBS containing 0.05% Tween 20 and 5% non-fat dry milk for 10 min each, the membrane was developed using an ECL™ Detection System (Amersham Pharmacia Biotech, Piscataway, N.J., USA).
RNA Isolation and Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Gastric cancer samples were obtained from patients who underwent gastrectomy at our institute and stored at -80 ° C until analysis. RNA isolation was performed using RNeasy Mini Kits (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. Complementary DNA (cDNA) synthesis and amplifi cation were carried out using Ready-To-Go™ You-Prime First-Strand Beads (Amersham Pharmacia Biotech). One microliter of the cDNA was used as a template for the specifi c PCR reaction. The primers used were as follows: ␤ -actin: forward 5 -ATG GAT GAT   GAT ATC GCC GCG-3 and reverse 5 -GAA GCA TTT GCG  GTG GAG GGG CC-3 , and PLK: forward 5 -GTC GTA GGA  TTC CAC GGC TTT T-3 and reverse 5 -TCC CCT ATT TTC  ACC TCC AGA T-3 . A GeneAmp™ PCR System 9600-R (Roche Diagnostic Systems, Tokyo, Japan) was used for the PCR amplifications. The PCR cycling conditions were as follows: initial denaturation (1 min at 94 ° C), followed by the appropriate number of cycles ( ␤ -actin, 40, and PLK, 30) of denaturation (94 ° C; ␤ -actin, 40 s, and PLK, 1 min), annealing ( ␤ -actin, 40 s at 58 ° C, and PLK, 1 min at 62 ° C) and elongation (72 ° C; ␤ -actin, 40 s, and PLK, 1 min), and a fi nal extension (5 min at 72 ° C). Thereafter, the samples were kept at 4 ° C until analysis. Seven-microliter aliquots of the products were separated in 1% agarose gel, stained with ethidium bromide and analyzed under UV light.
Immunohistochemistry
Patients and Tissue Specimens. Primary gastric carcinoma specimens were obtained from 160 patients treated surgically at our institution from 1981 to 1997. The patients were 89 males and 71 females, with a mean age of 61.3 years (range, 31-91 years). None of the patients had received preoperative adjuvant radiotherapy or chemotherapy. Clinicopathological fi ndings were determined according to the Japanese Classifi cation of Gastric Carcinoma [8] . All patients underwent either a distal partial, proximal partial or total gastrectomy with regional lymph node dissection to group 1 (D1), group 2 (D2) or group 3 (D3) with a curative intent. None of the resection margins was positive for tumors. Most of the patients with advanced tumor received postoperative chemotherapy with consecutive oral administration of uracil/tegafur at a dose of 300 mg daily for 1 year after surgery. Patients were periodically checked for early recurrence by diagnostic imaging (chest X-ray, double-contrast barium meal study, upper gastrointestinal fi berscopy, ultrasonography and computed tomography). All patients were monitored for at least 5 years. Informed consent was obtained from all subjects and/or their guardians.
Immunohistochemical Staining. The streptavidin-biotin-peroxidase method was applied for immunohistochemical staining using a Histofi ne SAB-PO kit (Nichirei, Tokyo, Japan). Briefl y, 4-mthick serial sections were dewaxed in xylene, dehydrated in ethanol, heated in a microwave oven (700 W) for 10 min to retrieve the antigens and then incubated in 3% hydrogen peroxide in methanol to block endogenous peroxidase. After washing with phosphate-buffered saline, the sections were incubated overnight at 4 ° C with either an anti-human PLK1 polyclonal antibody (1: 50 dilution; Oncogene), an anti-proliferating cell nuclear antigen (PCNA) monoclonal antibody (1: 100 dilution; DAKO, Glostrup, Denmark) or an anti-p53 monoclonal antibody (BP53; 1: 50 dilution; Novocastra Laboratories, Newcastle, UK). Following another wash with phosphate-buffered saline, the sections were incubated with a biotin-conjugated rabbit anti-mouse immunoglobulin antibody for 30 min, followed by incubation with a streptavidin-peroxidase complex for another 30 min. The immunohistochemical reactions were visualized using freshly prepared 3,3 -diaminobenzidine tetrahydrochloride. The sections were counterstained with methyl green and examined under a light microscope. Normal rabbit IgG was used instead of the primary antibodies for negative controls.
Evaluation of Immunostaining. Since weak staining of PLK1 was observed in the cytoplasm of normal epithelial cells, the intensity of the positive staining for PLK1 was evaluated by comparison with adjacent normal epithelial cells in the same section. When the intensity of positive staining in the tumor cells was stronger than that in the adjacent normal epithelial cells, PLK1 expression was evaluated as positive.
The PCNA-labeling index (PCNA-LI) was calculated as the percentage of positive tumor cells per 6 1,000 tumor cells. Briefl y, the stained sections were screened at a magnifi cation of ! 100 (objective lens: ! 10 and ocular lens: ! 10) under a light microscope (VANOX-S; Olympus, Tokyo, Japan) to identify fi ve regions in each section with the highest numbers of positive cells. The numbers of positive cells in these regions were then counted at a magnifi cation of ! 200 (objective lens: ! 20 and ocular lens: ! 10) and the mean numbers of positive cells were recorded. In the prognosis analysis, the patients were divided into high-and low-PCNA-LI groups, using the mean PCNA-LI value of 55.2 as the cutoff value.
The p53 immunoreactivity was graded as follows: positive, 1 20% of the carcinoma cells were stained; negative, no detectable expression or ! 20% of the carcinoma cells were stained, as reported previously [9] . All histological slides were examined by two observers (K.S. and S.T.) who were unaware of the clinical data or disease outcome. When the interpretation differed between the two observers, a reevaluation was carried out using a conference microscope to reach a fi nal decision.
Statistical Analysis
Associations of factors were evaluated by the 2 test and signifi cant differences among means were determined by the MannWhitney U test. Differences among survival curves based on PLK1 expression were examined by the log-rank test, and survival curves were constructed by the Kaplan-Meier method. Multivariate analysis of prognostic factors related to overall survival was performed using the Cox proportional hazards model and a stepwise procedure. The accepted level of signifi cance was p ! 0.05. A Macintosh personal computer system (StatView software; Abacus Concepts, Berkeley, Calif., USA) was used for all statistical analyses. 
Results
PLK1 Expression and Clinicopathological Findings
Relationships among PLK1 Expression, p53
Expression and PCNA-LI p53 expression and the PCNA-LI were determined in patients with advanced gastric carcinoma to assess the correlations among PLK1 expression, p53 expression and the PCNA-LI. p53 expression was observed in the nuclei 
PLK1 Expression and Prognosis
The 5-year survival rates of patients with negative and positive PLK1 expression were 75 and 54.8%, respectively, and the difference was signifi cant (p ! 0.05; fi g. 4 ). We employed the Cox proportional hazards model and a stepwise procedure to assess whether PLK1 expression represents an independent prognostic factor. The covariates included histological classifi cation, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, blood vessel invasion, p53 expression, PLK1 expression and the PCNA-LI. The results showed that PLK1 expression was an independent prognostic factor in addition to tumor size, p53 expression and the PCNA-LI ( table 3 ).
Previously, p53 expression and the PCNA-LI have been reported to be prognostic factors for gastric carcinoma [10, 11] . Moreover, we also found that PCNA-LI, p53 expression and PLK1 expression were independent prognostic factors in the current study. Therefore, we analyzed the prognosis according to either PLK1 and p53 expression or PLK1 expression and the PCNA-LI. The 5-year survival rates were 19.0, 51.9, 58.2 and 71.4% in patients with PLK1-and p53-positive tumors; PLK1-positive and p53-negative tumors; PLK1-negative and p53-positive tumors, and PLK1-and p53-negative tumors, respectively. The prognosis of patients with PLK1-and p53-positive tumors was signifi cantly worse than that of patients with PLK1-and p53-negative or PLK1-negative and p53-positive tumors ( fi g. 5 ). Moreover, the 5-year survival rates were 21.4, 54.2, 60.0 and 75.0% in patients with PLK1-positive and high-PCNA-LI tumors; PLK1- negative and high-PCNA-LI tumors; PLK1-positive and low-PCNA-LI tumors, and PLK1-negative and low-PCNA-LI tumors, respectively. Patients with PLK1-positive and high-PCNA-LI tumors showed a signifi cantly poorer prognosis than patients with PLK1-negative and/ or low PCNA-LI tumors ( fi g. 6 ).
Discussion
PLKs are a family of protein kinases that are known to regulate cell cycle events, particularly those that occur during mitosis. Recently, PLK1 has been reported to play critical roles during tumorigenesis. In fact, overexpression of PLK1 in NIH3T3 cells was able to transform these cells and induce tumors in nude mice [12] . Moreover, blocking PLK1 expression or function was shown to induce the apoptosis of certain cancer cells [13] . Since PLK1 is overexpressed in a variety of human malignancies, and its expression levels are often a prognostic factor for disease progression, tumor cells may depend on higher PLK1 levels for their growth and survival. However, there are few reports regarding PLK1 expression in gastric carcinoma. These fi ndings encouraged us to investigate the clinical signifi cance of PLK1 in gastric carcinoma in the current study.
We found that PLK1 was overexpressed in 52.5% of gastric carcinoma patients by immunohistochemistry. Since the gastrointestinal mucosa is a rapidly renewing tissue with a high proliferative rate, PLK1 was found to be weakly expressed in the normal gastric mucosa. However, a marked increase was only noted in the cancer tissues. These results are consistent with a previous report on colorectal cancers [14] . Of importance is that 65.2% of early gastric carcinomas overexpressed PLK1. Ito et al. [6] also reported that PLK1 overexpression is inversely correlated with tumor size in thyroid papillary carcinoma. Therefore, deregulated expression of PLK1 may be an early event in the progression of cancers, including gastric carcinoma.
There is abundant evidence from both in vivo and in vitro studies that PLK1 plays a crucial role in regulating the proliferative activity of malignant cells. In fact, Spankuch-Schmitt et al. [15, 16] recently demonstrated that depletion of PLK1 in tumor cell culture models dramatically suppresses cell proliferation. Takahashi et al. [14] reported a close correlation between PLK1 expression and proliferative activity evaluated by the PCNA-LI in colorectal cancers. PCNA is an intranuclear protein that is closely linked to the cell cycle and recognized as a useful marker for proliferating cells [17] . Our results also demonstrated a close correlation between PLK1 expression and the PCNA-LI in gastric carcinoma, indicating the possibility that PLK1 overexpression may be a key event related to the progression of gastric carcinoma.
p53 mutations are one of the most characterized genetic abnormalities in gastric carcinoma. p53 is a tumor suppressor gene localized on the short arm of human chromosome 17 (17p13.1) [18] that is mutated in a variety of human neoplasms, including gastric carcinoma. It has been reported that p53 protein overexpression detected by immunohistochemistry is a prognostic factor for many human neoplasms, such as gastric [19] , colon [20] and lung [21] carcinomas. Takahashi et al. [14] reported a relationship between PLK1 expression and p53 expression in colorectal cancer. However, we found no correlation between PLK1 expression and p53 expression in gastric carcinoma. The difference between our results and those of Takahashi et al. [14] may be due to the different types of cancer examined.
PLK1 overexpression has been reported to be correlated with poor survival in non-small cell lung cancers [22] , head-and-neck squamous cell cancers [23] , esophageal cancers [7] and ovarian cancers [24] . Our study also demonstrated that PLK1 expression was signifi cantly associated with a poorer prognosis for gastric carcinoma. Moreover, multivariate analysis indicated that PLK1 expression was an independent prognostic indicator. On the contrary, Tokumitsu et al. [7] showed that PLK mRNA expression was not a prognostic factor for gastric carcinoma. This difference appears to be due to contamination by normal epithelial cells, since we found weak PLK1 expression in these cells. Moreover, it has been reported that some other normal epithelial cells, such those in the ovary [24] , pancreas [25] and colon [14] , also express PLK1. Ito et al. [6] reported that infi ltrating lymphocytes also expressed PLK1. Therefore, in our opinion, contamination by normal and infi ltrating cells may affect the results for PLK mRNA expression, since the RT-PCR technique is quite sensitive. In fact, Takai et al. [26] demonstrated PLK mRNA expression in the normal endometrium. The frequency of PLK expression determined by RT-PCR (96.2%) was much higher than that determined by immunohistochemistry (52.5%) in the current study. This phenomenon may cause the differences between our results and those of Tokumitsu et al. [7] . To date, most previously published papers have applied immunohistochemistry to determine PLK1 expression in different cancers [6, 14, [24] [25] [26] [27] [28] [29] . Since immunohistochemistry enables us to distinguish cancer cells from normal cells, we consider that immunohistochemistry is a suitable method for determining PLK1 expression in gastric cancer. To our knowledge, this is the fi rst report to demonstrate that PLK1 expression is a prognostic indicator in patients with gastric carcinoma.
It has been reported that p53 expression and the PCNA-LI can serve as prognostic indicators [10, 11] . Therefore, we performed a combined analysis of PLK1 expression, p53 expression and the PCNA-LI with regard to prognosis. Patients with PLK1-and p53-positive tumors showed a signifi cantly shorter survival rate than those with PLK1-and p53-negative or PLK1-negative and p53-positive tumors. Moreover, patients with PLK1-positive and high-PCNA-LI tumors had a poorer prognosis than those with PLK1-negative and/or low-PCNA-LI tumors. These results indicate that combined evaluation of PLK1 expression, the PCNA-LI and p53 expression may be advantageous for a more accurate estimation of the prognosis in order to guide the treatment decisionmaking.
Given the crucial role of PLK1 in the development and progression of cancer, PLK1 may be a potential target for cancer therapy. In fact, Spänkuch et al. [30] reported that PLK1 depletion reduces tumor growth in nude mice [30] . Moreover, Guan et al. [31] depleted PLK1 expression using small interfering RNA and found growth inhibition and apoptosis induction in human cancer cell lines. Of importance is that PLK1 depletion reduces the survival of p53-defective cell lines and inhibits tumor growth in animal models. However, this phenomenon was not observed in most p53-expressing wild-type cells. These results demonstrate the possibility that the p53 status may strongly affect PLK1 function. In the current study, we observed a high frequency of PLK1 expression, even in early gastric cancer for which the prognosis is quite good. It has previously been shown that p53 accumulation is signifi cantly correlated with the depth of invasion in gastric carcinoma [32, 33] . Therefore, the differences in prognostic signifi cance of PLK1 between early and advanced gastric carcinoma may be due to the function of other molecules, such as p53. In fact, fi gure 5 shows that PLK1 expression is only signifi cantly correlated with prognosis in patients with p53-positive tumors.
Taken together, our data demonstrate that PLK1 expression may be a critical indicator of poor prognosis in patients with gastric carcinoma. Silencing of PLK1 using a small interfering RNA may be useful for the treatment of gastric carcinoma. Further studies are necessary to determine the precise functions of PLK1 in gastric carcinoma.
